Zacks Research Has Bullish Forecast for BMY Q1 Earnings

Key Points

• Analysts at Zacks Research have raised their Q1 2027 EPS estimate for Bristol Myers Squibb to $1.41, an increase from the previous estimate of $1.40.
• The company reported Q2 earnings of $1.46 per share, outpacing analysts' expectations of $1.07, with revenues significantly exceeding estimates at $12.27 billion.
• Bristol Myers Squibb declared a quarterly dividend of $0.62 per share, representing an annualized yield of 5.4%, with a payout ratio currently at 100%.

Bristol Myers Squibb Company (NYSE:BMY - Free Report) - Equities researchers at Zacks Research boosted their Q1 2027 EPS estimates for shares of Bristol Myers Squibb in a research note issued to investors on Wednesday, September 17th. Zacks Research analyst Team now forecasts that the biopharmaceutical company will post earnings of $1.41 per share for the quarter, up from their prior forecast of $1.40. The consensus estimate for Bristol Myers Squibb's current full-year earnings is $6.74 per share. Zacks Research also issued estimates for Bristol Myers Squibb's FY2027 earnings at $5.80 EPS.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The company had revenue of $12.27 billion for the quarter, compared to the consensus estimate of $11.32 billion. During the same quarter in the previous year, the company earned $2.07 EPS. Bristol Myers Squibb's quarterly revenue was up .6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS.

Other research analysts also recently issued research reports about the stock. Daiwa America downgraded shares of Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 5th. Morgan Stanley restated a "hold" rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. Wall Street Zen downgraded shares of Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a report on Friday, June 6th. Daiwa Capital Markets downgraded shares of Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 price objective on the stock. in a report on Tuesday, August 5th. Finally, Citigroup lowered their price objective on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating on the stock in a report on Friday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $56.38.

Bristol Myers Squibb Stock Down 1.2%

BMY traded down $0.55 during trading on Friday, hitting $45.05. 28,352,566 shares of the company's stock were exchanged, compared to its average volume of 9,937,920. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54. The business's 50 day moving average is $46.93 and its two-hundred day moving average is $49.66. Bristol Myers Squibb has a fifty-two week low of $42.96 and a fifty-two week high of $63.33. The stock has a market cap of $91.70 billion, a P/E ratio of 18.17, a PEG ratio of 2.30 and a beta of 0.35.

Institutional Trading of Bristol Myers Squibb

Institutional investors have recently made changes to their positions in the company. Brighton Jones LLC grew its position in Bristol Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company's stock valued at $1,116,000 after buying an additional 4,935 shares during the period. Bank Pictet & Cie Europe AG bought a new position in Bristol Myers Squibb during the fourth quarter valued at about $13,094,000. Waverly Advisors LLC grew its position in Bristol Myers Squibb by 140.0% during the fourth quarter. Waverly Advisors LLC now owns 32,099 shares of the biopharmaceutical company's stock valued at $1,816,000 after buying an additional 18,722 shares during the period. Continuum Advisory LLC grew its position in Bristol Myers Squibb by 15.1% during the fourth quarter. Continuum Advisory LLC now owns 1,733 shares of the biopharmaceutical company's stock valued at $98,000 after buying an additional 227 shares during the period. Finally, Kolinsky Wealth Management LLC bought a new position in Bristol Myers Squibb during the fourth quarter valued at about $204,000. Institutional investors own 76.41% of the company's stock.

Insider Activity

In other news, EVP David V. Elkins sold 56,000 shares of the company's stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total value of $2,650,480.00. Following the completion of the sale, the executive vice president owned 167,379 shares in the company, valued at $7,922,048.07. This represents a 25.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.09% of the stock is currently owned by insiders.

Bristol Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd will be paid a $0.62 dividend. The ex-dividend date is Friday, October 3rd. This represents a $2.48 annualized dividend and a dividend yield of 5.5%. Bristol Myers Squibb's dividend payout ratio is presently 100.00%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.